Previous 10 | Next 10 |
Stocks with share prices under $5 (aka " penny stocks ") are typically too risky to consider. The current economic environment, however, has pushed several intriguing, innovation-oriented companies into penny stock territory. Which beaten-down innovation stocks are worth checking out righ...
Precigen ( NASDAQ: PGEN ) priced an offering of ~42.86M common shares at $1.75 apiece to raise about $75M in gross proceeds. The company also granted the underwriters a 30-day option to buy up to an additional ~6.43M shares. Precigen plans to use the net proceeds for developin...
Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock PR Newswire GERMANTOWN, Md. , Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its c...
Precigen ( NASDAQ: PGEN ) commenced a $75M underwritten public offering of shares. The biopharmaceutical company also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25M shares. Precigen will sell all the shares in the offering. Sourc...
Precigen Announces Proposed $75.0 Million Public Offering of Common Stock PR Newswire GERMANTOWN, Md. , Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of $75.0 million of its c...
Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis PR Newswire – Repeated administrations of PRGN-2012 wer...
Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire – Company achieved significant progress for its clinical pipeline in 2022 – – Precigen to host R&D Day virtual event on Januar...
Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory Papillomatosis Precigen to Host a Virtual R&D Event on January 24t...
(NewsDirect) Acute myeloid leukemia (AML) is among the most common types of leukemia in adults. The term leukemia refers to cancers of the bone marrow and blood cells. Doctors refer to AML as “acute” because the condition is known to progress rapidly. The five-year s...
--News Direct-- Acute myeloid leukemia (AML) is among the most common types of leukemia in adults. The term leukemia refers to cancers of the bone marrow and blood cells. Doctors refer to AML as “acute” because the condition is known to progress rapidly. The five-yea...
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...